Steve. you, Thank
our continue us and employees, healthcare and the pandemic. maintaining preclinical, our the we operations patients by conduct made have the clinical, ongoing and to adjustments our programs To under safety allowed that imposed to the to conditions partners. commercial providers our advance we have date while continue believe We COVID-XX of
change was based at in Pharmaceuticals. AMAG as divestiture and operational And AMAG we a on value of from a disclosed reminder, previously AMAG's not XXXX, of have and Vyleesi the Vyleesi potential we strategic As Vyleesi. re-acquired on
like improve It's the Vyleesi After evaluation details accomplishments Steve plan, infrastructure a the to are not there undertook would had up infrastructure. commercial access, expanded we that directions, believe was that of patient experience commercial a infrastructure dramatically an I commercial redone, number of economics. was past that we've really a Vyleesi put from Under very mentioned, pharmacies the ground As extensive commercial with the all sub-optimal six rebuilt and patient he the Vyleesi. telemarketing, and properly, changes And we and product. on it of rebuild the of is very that stress to the as months re-acquired experience, the a profitability emphasize. to prescribers covered we experience. access relationships this in patient will this unfavorable and to over say specialty leading have patient distribution, place our we Vyleesi, And we have patient Steve’s be functioning the
ensuring and are expand. focus little partnership discussions. and we're potential improve of effective geo-targeting Vyleesi as in our improving position option A on Vyleesi accomplishments will are numbers re-license the treatment which now continued of for position These return results with hypoactive initial early, prescription Vyleesi substantial We efforts us beginning on the to a a strong to value to a in our objective women working manner a the Vyleesi disorder the a Vyleesi prescription put cost desire ongoing reimbursement, our to ultimate to our committed a investment. and available sexual efforts in demonstrate and to obtain premenopausal partner of
and clinical and we continue past Moving our advance on, had to results exciting pipeline programs pretty quarter. some the preclinical in
responses. sexual on is resolution primary of which inflammatory of in balance, regulation intake, our reminder, is function a system, As including energy focus and involved the food the melanocortin scientific
also system was resulted the Vyleesi approved treatment approval sexual desire of therapeutic as to women regulating melanocortin Our the the of first by function. research in FDA. its on FDA first discovery premenopausal based program on-demand was role melanocortin Also the first the work with Vyleesi and for sexual based melanocortin the This disorder. in by note, hypoactive
the on to is system target focus and that ability research reduce drugs melanocortin the or of current fibrosis. resolve down inflammation turn developing Our
believe melanocortin-based treating to We have working a potential a are will significant we diseases. variety build portfolio in ocular that of therapeutics of
have clinical candidates disease as drug diseases non-infectious and corneal indication, diseases. eye such We uveitis, ocular developed for other disease, retinal stage dry
We also such candidate for ulcerative gastrointestinal colitis. stage drug delivered clinical orally disease a have as
and Our sicca the required irritation, December endpoints the disease The disease first a advancement which tolerability its a melanocortin conjunctiva the by cornea dry safety, signs resulting PLXXXX. objective, disease study disease. subjects X provide therapeutic multiple sign of dry as has eye met of detailed in discomfort, our XXXX. of of delivered PLXXXX. continue efficacy disease. in study and and Phase in which eye reported corneal dry where measure study Dry The provide a of primary and eye affects symptom improvement as of keratoconjunctivitis also multiple eye symptoms measured secondary the positive was identified which and the data symptoms to to the is data topical There dry known achieved The topically of of eye staining, ocular is We eye the blurry delivered and and reduce dry symptoms and included of inferior XX-week endpoints believe multiple delivered disease. evaluated many data also we activating weeks or PLXXXX by an varied, over dry placebo a Phase The fluorescein the co-primary Causes no was to population topically a enrolled inflammation overview effects improvements melanocortin system eye pain, safety the after of study vision. XXX study the tolerability. in and that PLXXXX significant of signs are eye were PLXXXX visit. treatment negative to underlies locally disease. study resolve signals the and that redness, moderate dosing and signs a PLXXXX statistically delivered comparing and X The PLXXXX at on severe period. excellent multi-center, And will randomized aspects ocular was two patient of improving control of had XX-week
However, for of patients. corneal population In including inferior, for nasal achieved moderate, staining, staining, sub-populations peptide discomfort. superior two primary significance was and in included ocular signs total mild, ocular conjunctival weeks at severe patient, and XX that overall total the and to statistical [indiscernible] significance multiple statistical and endpoints temporal week symptoms including moderate fluorescein multiple severe the enrolled not achieved the PLXXXX and
and Additionally, measures multiple significance. symptom trended toward sign
PLXXXX disease both treatment. corneal us in important was this first note, to and it's the improvement and were our the identify to X/X half Positive course have start development the conjunctival disease first study PLXXXX and FDA over X of with the of as for allowed continued eye eye that for with study time start the showing in meeting inflammation. an think study dry pathway dry We're and mid-XXXX preparing patient endpoint, readouts effects targeted maintained the regulatory I were for disease. to Results a point in of treatment dry in two broad-based and the PLXXXX the in the results data is population weeks end XXXX. earliest active of of seems Phase Phase currently with eye of clinical
year. Annual in of the for multi-billion the potential will we ocular the concluded Research has study in eye summary, profile the Phase of dollar detailed reasonably disease its dry and this emerging As profile penetration reminder at data believe confirmed in market. presented potentially May X results excellent If PLXXXX into from is advance distinct rapid In Meeting are a substantial be Ophthalmology therapeutic for PLXXXX tolerability the the studies, early Vision Association of with therapy. clinical dry a in onset a and market that
diseases. posterior ocular earlier dry divided eye, anterior diseases to have disease broad in categories, eye, transplant. As the melanocortin two ocular as corneal and or segment. based segment, believe can of potential anterior the the the for that of front call, we The Treatments be includes therapeutics such segment of eye back or treat variety diseases into a stated
anticipate We diseases anterior disease by our anterior various retinopathies uveitis. clinical on are mid-XXXX. segment making Posterior segment additional for indications indications decision and evaluating include and segment next candidates
a advance retinal to planning indication for disease forward well. as clinical mid-XXXX are We treating by candidate a
proof-of-concept we activities PLXXXX targeted patient enrollment with orally Phase the potential a to results colitis. the delivered our on readout positive, half to of conducting data as designed melanocortin ulcerative for to Moving to This and start for which license are of selective will study efforts X-receptor PLXXXX. potential second in of a our oral is the formulation XXXX. required agonist will to in our the first of the treatment a conduct XXXX be the colitis, This If PLXXXX. X evaluate support evaluate clinical efficacy study will safety study study, ulcerative
our particular we COVID-XX for continue required following pulmonary to patients, studies. PLXXXX IND clinical the and for conduct to treatment conduct activities indications Regarding in
reduce patients with associated fibrosis COVID-XX treatment lung and disease. for As a potential the with inflammation PLXXXX infection, may
patients PLXXXX is calls, design, the previous evolving, landscape studies and funding. patients. on COVID discussed new conducting As in conduct which uncertainties studies of and COVID-XX impacted rapidly to releases that XX-K, COVID-XX ability conducting studies started dependent our risks our with on is in and patients external clinical study for on clinical clinical risk COVID-XX in Based press
look promising program. very We continue to finding support external seek hopefully this and forward support for to
research the the preliminary based The We enrolling medical centers, last is XXXX. X clinical is clinical grant PLXXXX, disease naturally and work in ongoing. patients study anticipate supported is year, Late from peptide is heart began Finally, academic with Heart A our receptor selective data two in peptide agonist cooperation on by our Association. in American on a ejection in candidate patients and major Phase with study system, being currently fraction. which a is evaluated naturally preserved drug an a study
on You been our operations of www.palatin.com. immediate we business directors Addressing acted pandemic, safety patients, and employees website, action ensure partners. and healthcare of additional could the advance programs management, our the adjust on pandemic, quickly have COVID-XX our the able took the and response In to our information to executive to to continue to board we our find employees, the programs.
advance, us ability to strong our our will from to pandemic programs, emerge Our – a cash strong the position. allow Palatin development and position in
deficiencies significant we we that inherited in have have Pharmaceuticals. an progress. from Wills team activities AMAG addressed extra Steve directions commercial the put has Vyleesi place Our made Under commercial
We of have selective now Vyleesi. the begun marketing
Chinese work partners, now with their studies Korean our into Vyleesi regulatory support and are We advancing submissions. clinical and continue to to which
X/X first our results For as completed start in the of part Phase the are study for of X preparing the a dry mid-XXXX. we study eye disease program, and Phase
second half ocular addition, with clinical new starting based melanocortin additional studies we therapeutics build to indications product In the XXXX. our and portfolio in continue of
thank look to we we adjustments rest call new the Palatin now we of advancement will open and team their for And to questions. a forward have to As continued dedication working remain a all on In will closing, I of strong our their pipeline environment the clinical partners rapid of and the our we like focused their novel to advancement. XXXX, would of and programs. candidates
